Trials / Completed
CompletedNCT02096081
The Treatment of Glabellar Frown Lines
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 250 (actual)
- Sponsor
- Merz North America, Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).
Detailed description
This is a prospective, multicenter, randomized, double-blind, parallel group clinical study to investigate the equivalence of incobotulinumtoxinA (Xeomin®) to onabotulinumtoxinA (Botox®) in the treatment of glabellar frown lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IncobotulinumtoxinA | 20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection |
| DRUG | OnabotulinumtoxinA | 20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2014-08-01
- Completion
- 2014-11-01
- First posted
- 2014-03-26
- Last updated
- 2017-10-19
- Results posted
- 2017-03-16
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02096081. Inclusion in this directory is not an endorsement.